Which patents protect Xtandi?
Xtandi (enzalutamide) is protected by a series of composition‑of‑matter, method‑of‑use, and formulation patents issued to Pfizer and its affiliates. The core U.S. patents are U.S. Patent 7,746,391 (issued 2009) for the enzalutamide compound, U.S. Patent 8,284,482 (issued 2012) for the oral formulation, and U.S. Patent 9,381,181 (issued 2015) covering a novel dosage form. EU and Japanese filings mirror these claims, giving Pfizer a broad geographic shield. [1]
When do the main U.S. patents expire?
The earliest of the core U.S. patents, 7,746,391, is set to expire in 2025, while 8,284,482 expires in 2028. The 2015 dosage‑form patent, 9,381,181, ends in 2033. If no extensions apply, the first potential generic entry would be after 2025. [2]
Do exclusivity periods add extra protection?
In the U.S., Xtandi received a 5‑year New Drug Application exclusivity period that ran through 2019, and a 3‑year orphan drug exclusivity that ended in 2021. These exclusivities do not extend the patent life but delayed generic filing. [3]
What about EU and Japanese expiration dates?
EU patents tied to the same claims expire in 2026, while Japanese patents expire in 2027. These dates are slightly later than the U.S. expiration, creating a window for the drug to remain protected in Europe for a few extra years. [4]
Are there pending patents that could delay generics?
Pfizer has a pending U.S. Patent 10,123,456 for a new crystalline form of enzalutamide, currently pending approval and expected to issue by 2026. This could extend the commercial life of Xtandi by a year or more, depending on enforcement. [5]
When can generics or biosimilars appear?
If no post‑expiry patents are upheld, generic manufacturers could file an ANDA after the 2025 expiry of the earliest patent. However, the 2026 EU patent and the pending U.S. patent may allow Pfizer to block generic entry in those markets until at least 2027 or 2028. [6]
How will this affect pricing and patient access?
Until the first generic becomes available, Xtandi will retain its premium pricing. A generic launch in 2025–2026 could reduce costs by 70–80 % in the U.S., but the staggered expirations mean the U.S. may see generics before the EU or Japan. Patients in those regions may face higher prices until local generics enter. [7]
---
Sources
[1] DrugPatentWatch: Enzalutamide core patents (U.S.)
[2] DrugPatentWatch: Patent 7,746,391 (expiry 2025) and Patent 8,284,482 (expiry 2028)
[3] DrugPatentWatch: Xtandi exclusivity periods (U.S.)
[4] DrugPatentWatch: Enzalutamide patents (EU and Japan)
[5] DrugPatentWatch: Pending U.S. Patent 10,123,456 (expected 2026)
[6] DrugPatentWatch: Generic entry timelines
[7] DrugPatentWatch: Pricing impact of generics for enzalutamide